Shares of Synthetic Biologics Inc (NYSE:SYN) have been given a consensus broker rating score of 1.20 (Strong Buy) from the five analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and four have issued a strong buy rating on the company.

Brokers have set a twelve-month consensus price objective of $7.44 for the company and are forecasting that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also given Synthetic Biologics an industry rank of 92 out of 265 based on the ratings given to its competitors.

Several equities research analysts have recently issued reports on SYN shares. Zacks Investment Research raised Synthetic Biologics from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a report on Tuesday, May 31st. FBR & Co reaffirmed a “buy” rating on shares of Synthetic Biologics in a report on Friday, August 5th. BTIG Research began coverage on Synthetic Biologics in a research note on Thursday, August 25th. They set a “buy” rating and a $5.00 price objective on the stock. Finally, Griffin Securities set a $5.80 price objective on Synthetic Biologics and gave the stock a “buy” rating in a research note on Wednesday, August 31st.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Synthetic Biologics (NYSE:SYN) traded down 0.58% on Tuesday, hitting $1.70. The stock had a trading volume of 126,483 shares. Synthetic Biologics has a 1-year low of $0.93 and a 1-year high of $3.25. The stock’s 50-day moving average is $1.66 and its 200 day moving average is $1.96. The firm’s market capitalization is $155.16 million.

Synthetic Biologics (NYSE:SYN) last issued its earnings results on Wednesday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.02. On average, equities research analysts predict that Synthetic Biologics will post ($0.39) earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KCG Holdings Inc. acquired a new position in Synthetic Biologics during the second quarter worth approximately $106,000. Rhumbline Advisers acquired a new position in Synthetic Biologics during the second quarter worth approximately $126,000. Schwab Charles Investment Management Inc. acquired a new position in Synthetic Biologics during the second quarter worth approximately $213,000. Teachers Advisors Inc. acquired a new position in Synthetic Biologics during the second quarter worth approximately $216,000. Finally, BlackRock Investment Management LLC boosted its position in Synthetic Biologics by 2,517.2% in the second quarter. BlackRock Investment Management LLC now owns 282,158 shares of the company’s stock worth $508,000 after buying an additional 271,377 shares in the last quarter.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

5 Day Chart for NYSE:SYN

Get a free copy of the Zacks research report on Synthetic Biologics (SYN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with's FREE daily email newsletter.